⌘K
t
GENinCode Plc announced that all resolutions were duly passed at its Annual General Meeting held today, 30 June 2025. A copy of the voting results will be available on the company's website later today.
| Date | 30 Jun 2025 |
| Time | 11:42:15 |
| Category | AGMs and other meetings |
| ID | 9992O |
GENinCode Plc
("GENinCode" or the "Company")
Result of AGM
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
A copy of the voting results can be found on the website later today here.
For more information visit www.genincode.com
Enquiries:
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
|
|
Matthew Walls, CEO |
|
|
|
Paul Foulger, CFO |
||
|
Cavendish Capital Markets Limited |
Tel: +44 (0)20 7397 8900 |
|
|
Giles Balleny (Corporate Finance) |
||
|
Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) |
||
|
Dale Bellis / Michael Johnson (Sales) |
||
|
Walbrook PR Limited Anna Dunphy / Rachel Broad / Marcus Ulker |
Tel: 020 7933 8780 or genincode@walbrookpr.com |
|
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.